[go: up one dir, main page]

MX2013008367A - Firmas de esxpresion genetica de cancer de colon y metodos de uso. - Google Patents

Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Info

Publication number
MX2013008367A
MX2013008367A MX2013008367A MX2013008367A MX2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A MX 2013008367 A MX2013008367 A MX 2013008367A
Authority
MX
Mexico
Prior art keywords
colon cancer
methods
gene expression
cancer gene
expression signatures
Prior art date
Application number
MX2013008367A
Other languages
English (en)
Inventor
Denis Paul Harkin
Vitali Proutski
Julie Black
Peter Kerr
Richard Kennedy
Andreas Winter
Timothy Davison
Max Bylesjo
Vadim Farztdinov
Claire Wilson
Robert James Holt
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of MX2013008367A publication Critical patent/MX2013008367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/57535—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una firma de expresión genética de cáncer de colon, microarreglos que la incluyen y métodos de uso de la firma de expresión genética de colon. La firma de expresión genética es especialmente útil para determinar la prognosis de un paciente diagnosticado con cáncer de colon, tal como cáncer de colon etapa II. La firma genética descrita en la presente es también útil para determinar la efectividad de resección quirúrgica con o sin quimioterapia adyuvante y determinar la posibilidad de recurrencia de cáncer en pacientes con cáncer de colon.
MX2013008367A 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso. MX2013008367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161435922P 2011-01-25 2011-01-25
PCT/US2012/022594 WO2012103250A2 (en) 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use

Publications (1)

Publication Number Publication Date
MX2013008367A true MX2013008367A (es) 2013-08-12

Family

ID=46581385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008367A MX2013008367A (es) 2011-01-25 2012-01-25 Firmas de esxpresion genetica de cancer de colon y metodos de uso.

Country Status (14)

Country Link
US (1) US10196691B2 (es)
EP (1) EP2668296B1 (es)
JP (1) JP2014509189A (es)
KR (1) KR20140006898A (es)
CN (1) CN103403543B9 (es)
AU (1) AU2012209074A1 (es)
BR (1) BR112013018924A2 (es)
CA (1) CA2825218A1 (es)
EA (1) EA201391074A1 (es)
IL (1) IL227643A0 (es)
MX (1) MX2013008367A (es)
SG (1) SG192108A1 (es)
WO (1) WO2012103250A2 (es)
ZA (1) ZA201305024B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
HUE026666T2 (en) 2010-04-05 2016-07-28 Prognosys Biosciences Inc Spatially encoded biological assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US20130074201A1 (en) * 2011-09-16 2013-03-21 The Johns Hopkins University Cancer-specific genetic rearrangements
EP3901280B1 (en) * 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
CN118345148A (zh) 2013-06-25 2024-07-16 普罗格诺西斯生物科学公司 检测样品中生物靶标的空间分布的方法和系统
US9652722B1 (en) * 2013-12-05 2017-05-16 The Mathworks, Inc. Methods and systems for robust supervised machine learning
CA2939697A1 (en) * 2014-02-17 2015-08-20 Ventana Medical Systems, Inc. G-alpha, interacting vesicle associated protein (giv) as a predictive marker in stage ii colorectal cancer
US10407737B2 (en) 2014-04-10 2019-09-10 Bio-Marcare Technologies Ltd. Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
US10774374B2 (en) 2015-04-10 2020-09-15 Spatial Transcriptomics AB and Illumina, Inc. Spatially distinguished, multiplex nucleic acid analysis of biological specimens
CN108020672A (zh) * 2016-11-03 2018-05-11 中国医学科学院基础医学研究所 检测rhbdd1蛋白的elisa方法及试剂盒
US20200088748A1 (en) * 2016-12-08 2020-03-19 Dana-Farber Cancer Institute, Inc. Metabolic profiling of fixed samples
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
CA3088754A1 (en) * 2018-01-22 2019-07-25 Liquid Biopsy Research LLC Methods for colon cancer detection and treatment monitoring
AU2019252672B2 (en) 2018-04-12 2025-08-14 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
CN111321220A (zh) * 2018-12-14 2020-06-23 中国医学科学院肿瘤医院 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统
CN110079607B (zh) * 2019-04-04 2022-08-02 陕西师范大学 一种引物组、检测血液样品种属的方法及应用
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
EP4158054B1 (en) 2020-06-02 2025-04-16 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
ES2981265T3 (es) 2020-06-08 2024-10-08 10X Genomics Inc Métodos para determinar un margen quirúrgico y métodos de uso del mismo
US20230235408A1 (en) * 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
CN111951883A (zh) * 2020-08-04 2020-11-17 广东省第二人民医院（广东省卫生应急医院） 一种特征mRNA表达谱组合及结肠癌早期预测方法
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用
WO2024206495A2 (en) * 2023-03-27 2024-10-03 Immunis.Ai, Inc. Active surveillance and risk stratification for prostate cancer
CN119372311A (zh) * 2024-09-30 2025-01-28 东南大学 基于成纤维细胞相关基因的结肠癌预后和治疗抵抗预测模型的构建方法和应用
CN120009551B (zh) * 2025-02-27 2025-08-15 西南医科大学 剪接因子wbp11及其抑制剂的用途、预防或治疗结直肠癌的药物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155950B1 (en) 1983-09-02 1990-01-17 Molecular Biosystems, Inc. Oligonucleotide polymeric support system
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
WO1995030774A1 (en) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
CA2195209C (en) 1994-07-15 2008-09-23 Roy R. Sooknanan Use of rna polymerase to improve nucleic acid amplification process
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
EP1736554B1 (en) 1996-05-29 2013-10-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
WO2001073027A2 (en) 2000-03-24 2001-10-04 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040146921A1 (en) 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
US20050287544A1 (en) 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
KR20070052694A (ko) 2004-01-09 2007-05-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 유전자 발현을 위한 세포-유형-특이적 패턴
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
WO2005118878A2 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
CA2586201A1 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
NZ593224A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
US20100009905A1 (en) * 2006-03-24 2010-01-14 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer
US20100261169A1 (en) * 2007-01-29 2010-10-14 Shira Wallach Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
BRPI0912046B1 (pt) * 2008-05-27 2020-11-24 Agilent Technologies, Inc Composições de hibridizaqao e seu uso, bem como metodo de hibridizaqao de sequencias de acido nucleico
WO2010060055A1 (en) 2008-11-21 2010-05-27 Duke University Predicting cancer risk and treatment success

Also Published As

Publication number Publication date
BR112013018924A2 (en) 2018-05-08
CN103403543A (zh) 2013-11-20
NZ612471A (en) 2015-11-27
AU2012209074A1 (en) 2013-07-11
SG192108A1 (en) 2013-08-30
CN103403543B9 (zh) 2017-05-17
ZA201305024B (en) 2014-03-26
US20140094379A1 (en) 2014-04-03
EP2668296B1 (en) 2018-08-15
CN103403543B (zh) 2016-11-09
KR20140006898A (ko) 2014-01-16
WO2012103250A3 (en) 2012-10-11
EA201391074A1 (ru) 2013-12-30
EP2668296A2 (en) 2013-12-04
JP2014509189A (ja) 2014-04-17
CA2825218A1 (en) 2012-08-02
EP2668296A4 (en) 2015-09-02
IL227643A0 (en) 2013-09-30
WO2012103250A2 (en) 2012-08-02
US10196691B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
MX2013008367A (es) Firmas de esxpresion genetica de cancer de colon y metodos de uso.
IL268974B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
CY1118001T1 (el) Νεες ctla4-ig προσκολλητινες
CR20120406A (es) Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa
CL2017001110A1 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
EA201171367A1 (ru) Винилиндазолильные соединения
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
CY1121185T1 (el) Αδενοϊος που εκφραζει fas-χιμαιρα και χρηση αυτης σε μεθοδους θεραπειας καρκινου
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
GT201500249A (es) Terapia de combinación
EA201590650A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
AR090129A1 (es) Oligonucleotidos para la modulacion de la expresion genica y sus usos
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
WO2013028554A3 (en) Gene signatures for lung cancer prognosis and therapy selection
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2015002749A (es) Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas.
MX2015001788A (es) Metabolitos de metionina predicen la evolución agresiva del cáncer.
BR112012025196A2 (pt) prognóstico com base genética da reincidência do antígeno prostático específico (psa) para pacientes com câncer de próstata clinicamente localizado
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata